<DOC>
	<DOCNO>NCT02436928</DOCNO>
	<brief_summary>This study aim evaluate safety immunogenicity inactivate cell culture derive H7N9 vaccine healthy adult subject .</brief_summary>
	<brief_title>A Study Evaluate Safety Immunogenicity H7N9 Influenza Vaccine ( AT-501 ) Healthy Adult Subjects</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Influenza Birds</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Subject within age limit range , free obvious health problem judge investigator enter study . 2 . Female subject must : either nonchildbearing potential , one year postmenopausal ; , childbearing potential , must abstinent use adequate contraceptive precaution 30 day prior receive study vaccination , negative pregnancy test must agree continue precaution two month completion vaccination series . 3 . Subject willing able comply require study visit followup require protocol . 4 . Subject must provide write informed consent Subjects ' legal representative must understand consent procedure . 1 . Subjects previous know potential exposure avian influenza virus H7N9 HA antigen avian influenza include H5N1 . 2 . Subjects seasonal influenza vaccine within 6 month prior enrolment seasonal influenza vaccine time study period 3 . Subjects administered vaccine period within 6 week first administration study vaccine . 4 . Subjects confirm suspect abnormal immune function , immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection , base medical history physical examination . 5 . Subjects history hypersensitivity vaccine history allergic disease reaction likely exacerbate component vaccine . 6 . Subjects history inflammatory degenerative neurological disease . 7 . Subjects receive chronic administration immunosuppressant immunemodifying drug within 6 month prior administration study vaccine . Inhaled topical steroid allow . 8 . Known HIV , hepatitis B ( HBsAg ) hepatitis C seropositivity . 9 . Subjects , judge investigator , clinically significant medical illness include acute pulmonary , cardiovascular , hepatic renal functional abnormality , determine medical history , physical examination and/or laboratory screen test . 10 . The subject would suitable vaccination screen laboratory test show follow ALT AST &gt; upper limit normal range ( ULN ) ; Serum creatinine &gt; upper limit normal range ( ULN ) ; Any significant laboratory abnormality judge investigator 11 . Subjects receive administration immunoglobulin and/or blood product within 3 month precede administration study vaccine time study . 12 . Subjects acute disease time enrolment . 13 . Use investigational nonregistered product study vaccine within 30 day prior first vaccination , plan use abovementioned product entire study period . 14 . Psychiatric , addictive , disorder , may compromise ability give truly informed consent participation study adequate compliance . 15 . Any clinically relevant disease and/or abnormal laboratory finding ( , , opinion Investigator , may either put patient risk participation study , influence result study , patient 's ability participate study . 16 . Breast feed pregnant woman refusal submit urine test rule pregnancy prior enrolment study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>H7N9 Influenza</keyword>
	<keyword>Avian influenza A</keyword>
	<keyword>cell culture derive</keyword>
</DOC>